125P - Levels of miR-17, miR-21, miR-29a and miR-92 as recurrence markers after adjuvant chemotherapy in Nx lymph node status colon cancer patients

Date 10 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Colon and Rectal Cancer
Translational Research
Basic Principles in the Management and Treatment (of cancer)
Presenter Nikolay Conev
Citation Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363
Authors N.V. Conev1, A. Konsoulova-Kirova2, J. Kashlov3, I. Tonev4, I. Donev2
  • 1Dept. Of Medical Oncology, St. Marina University Hospital, 9000 - Varna/BG
  • 2Dept. Of Medical Oncology, St. Marina University Hospital, 9010 - Varna/BG
  • 3Dept. Of Internal Diseases, St. Marina University Hospital, 9010 - Varna/BG
  • 4Oncology Clinic, Complex Cancer Center, 4004 - Plovdiv/BG



The benefit of adjuvant chemotherapy in II and III stage patients with colon cancer (CC) is determined in large-scale trials. Despite the surprisingly large number of Nx cases (less than 12 lymph nodes examined), the potential benefit of adjuvant chemotherapy is not known and there are only a few biomarkers that could predict recurrence of the disease. Recent evidence suggests that microRNAs are important cancer markers.


CC patients (n = 18) with Nx lymph node status, who have undergone radical surgery and have completed 5-FU based adjuvant chemotherapy were included. Serum after last cycle of adjuvant chemotherapy was obtained and patients were followed-up regularly for 1 year of follow-up. Real-time reverse transcription quantitative polymerase chain reaction was used to measure the expression levels of miRNAs (miR-17, miR-21, miR-29a and miR-92), in the patients' samples and in 7 healthy individuals, as a control group.


Seven patients from the tested group experienced recurrence after 1 year of follow-up. Within the Nx patients all miRNAs except miR-29a had significant differences in expression levels between the recurred patients vs non recurred patients groups. The area under the receiver operating characteristic curve (AUCs) used to evaluate the predictive performance of the miR-17, miR-21, miR-92 for Nx patients were 0.844, 0.948, and 0.935, respectively (p 


This study suggests that the expression levels of the tested serum miR-21, miR-17 and miR-92 in Nx patients with CC who underwent radical surgery and adjuvant chemotherapy may have diagnostic value for differentiating between recurred and non-recurred patients.

Clinical trial identification

Legal entity responsible for the study

Ivan Donev


Medical University Varna


All authors have declared no conflicts of interest.